Navigation Links
Can EP4 agonist alleviate gastric lesions?
Date:11/18/2009

Over 300 million patients use non-steroidal anti-inflammatory drugs (NSAIDs) in the world to treat pain, arthritis, fever and other diseases. Nearly 30% of the users suffer from gastric lesions and bleeding. To mitigate NSAIDs' adverse effects on the stomach, misoprostol, a non-selective prostaglandin E1 (PGE1) analogue, has been prescribed as the first choice for prevention of NSAID-induced injuries, but often induces severe adverse effects. There remain unmet medical needs for drugs with improved therapeutic profiles.

A research article published on November 7, 2009 in the World Journal of Gastroenterology addresses this question. A research team from United States investigated therapeutic potentials of a highly-selective EP4 agonist for treatment of a mouse gastric ulcer model in the presence or absence of indomethacin at various levels.

They found the EP4-selective agonist reduced high dose indomethacin-induced acute hemorrhagic damage and promoted mucous epithelial regeneration. Low-dose indomethacin aggravated ulcer bleeding and inflammation, and delayed the healing of the established chronic gastric ulcer. The EP4 agonist, when applied locally, not only offset indomethacin-induced gastric bleeding and inflammation, but also accelerated ulcer healing. In the absence of indomethacin, the EP4 agonist even accelerated chronic gastric ulcer healing and suppressed inflammatory cell infiltration in the granulation tissue. In vitro, the EP4 agonist protected human gastric mucous cells from indomethacin-induced apoptosis.

Their results suggest that EP4 agonists may mimic the gastric protective effects of PGE2 in the presence or absence of NSAIDs, and may show advantages over non-selective analogs such as misoprostol by minimizing adverse effects arising from activating all 4 subtype receptors of PGE2.


'/>"/>

Contact: Ye-Ru Wang
wjg@wjgnet.com
86-105-908-0039
World Journal of Gastroenterology
Source:Eurekalert

0

GOOD

Page: 1

Related medicine news :

1. How IAP antagonist chemicals kill tumors
2. Exelixis to Receive Milestone Payment From Bristol-Myers Squibb for Achievement of Liver X Receptor Agonist Development Milestone
3. TNF-alpha antagonist stops inflammation-induced colon cancer in its tracks
4. TorreyPines Therapeutics Licenses Intellectual Property from Johns Hopkins Related to Novel Uses of Glutamate Receptor Antagonists for Prevention, Treatment of Stroke, Heart Attack
5. Galenea and Organix Announce Exclusive License Agreement for 5-HT2C Agonists for the Treatment of Obesity
6. TorreyPines NGX426, an Oral AMPA/Kainate Receptor Antagonist, Meets Primary Endpoints in Reducing Capsaicin-Induced Pain in Healthy Subjects
7. GlaxoSmithKline Statement on FDA Advisory Committee Vote on Use of Asthma Medicines Containing Long-Acting Beta-Agonists
8. Amira Announces the Successful Completion of GLP Toxicity Studies for a Novel DP2 Antagonist.
9. Shionogi Announces Positive Top-Line Efficacy Results from Year-Long Studies of Velneperit, a Novel NPY Y5 Receptor Antagonist Being Investigated for the Treatment of Obesity
10. Arena Pharmaceuticals Announces Initiation by Merck of Phase 2 Clinical Trial of Niacin Receptor Agonist
11. FDA Approves SAMSCA(TM) (tolvaptan), the First and Only Oral Vasopressin Antagonist to Treat Patients With Clinically Significant Hypervolemic and Euvolemic Hyponatremia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2013)... Beginning May 21st, 2013, DTP Sales ... 8000, the newest in digital recording technology, to the ... product for anyone looking to get the most from ... 8000 is expected to have revolutionary options and ... voice recorder features and highlights: , ...
(Date:5/21/2013)... (PRWEB) May 21, 2013 Tools4ever, the ... has made its Self Service Reset Password Management (SSRPM) ... employees can now use the service on mobile systems ... end users can easily reset their Windows passwords anywhere, ... of questions correctly, the user may then reset his ...
(Date:5/21/2013)... HealthDay Reporter , , MONDAY, May 20 ... millions of people with chronic obstructive pulmonary disease ... among older patients, a new large Canadian study ... age 65 who are prescribed long-acting bronchodilators -- ... as Serevent). Both medications are commonly used to ...
(Date:5/21/2013)... PHILADELPHIA The surgical management of non-small cell lung ... the race of the patient, according to a new ... I and Stage II NSCLC is surgery," said researcher ... in Omaha, Nebraska. "In our study of more than ... the years 2000 and 2010, we found statistically significant ...
(Date:5/21/2013)... 2013, PHILADELPHIA ─ A novel approach to obstructing ... of asthma has shown promise in a Phase ... , Their research will be presented at the ... simultaneously online in the New England Journal ... trial tested the efficacy and safety of the ...
Breaking Medicine News(10 mins):Health News:DTP Sales & Service Announces Upcoming Availability Of Philips Pocket Memo 8000 Series 2Health News:Tools4ever’s password reset software ready for BYOD 2Health News:Certain COPD Meds Might Raise Heart Risks, Study Says 2Health News:Certain COPD Meds Might Raise Heart Risks, Study Says 3Health News:Monoclonal antibody appears effective and safe in asthma Phase IIa trial 2Health News:Monoclonal antibody appears effective and safe in asthma Phase IIa trial 3
... of the Board, SAN DIEGO, Aug. 30 ... board of directors has unanimously approved a,succession plan for ... T. Gallahue will be promoted to Chief Executive Officer ... will succeed Dr. Peter,C. Farrell, 65. As of January ...
... following is a,memorandum to editorial writers and columnists:, ... Communications,Director, SUBJECT: Katrina Storm Warning, On ... New Orleans,and the Gulf Coast are struggling to ... disasters in U.S. history. Disaster often strikes suddenly,and ...
... air pollution, aging are main causes of spread worldwide, ... There are more people around the world suffering from ... international team of researchers reports. , Worse yet, those ... continues to age, claims the study in the Sept. ...
... Aug. 30 Omnicell, Inc.,(Nasdaq: OMCL ) a ... and operational efficiency in healthcare,facilities, today announced that Randall ... president & CFO will present at the Thomas Weisel,Partners ... Mass.,on Wednesday, September 5, 2007 at 11:30 a.m. Eastern ...
... Aug. 30 The following was issued,today by Active ... Executive Director, Active Minds, Inc. WHAT: Ms. Malmon ... student advocacy, including depression and suicide Ms. Malmon ... is,nationally recognized for her unique peer-to-peer approach in addressing,the ...
... N.C., Aug. 30 Cogdell Spencer Inc.,(NYSE: ... acquired Summit,Professional Plaza I and II in Brunswick, ... building complex totals 97,472 square feet and is,98 ... new market and new client relationship,for Cogdell Spencer. ...
Cached Medicine News:Health News:ResMed Names Kieran Gallahue as Chief Executive Officer, Effective January 1, 2008. 2Health News:Campaign for America's Future Memorandum: Katrina Storm Warning 2Health News:Campaign for America's Future Memorandum: Katrina Storm Warning 3Health News:Campaign for America's Future Memorandum: Katrina Storm Warning 4Health News:Campaign for America's Future Memorandum: Katrina Storm Warning 5Health News:Prevalence of COPD Greater Than Thought 2Health News:Prevalence of COPD Greater Than Thought 3Health News:Omnicell to Present at Thomas Weisel Healthcare Conference 2007 2Health News:College Mental Health Expert and Sister of Student Who Died By Suicide Available to Discuss College Mental Health Issues 2Health News:Cogdell Spencer Inc. Acquires Summit Professional Plaza I and II in Brunswick, Georgia 2
(Date:5/21/2013)... 2013   RxAlly , a first-of-its-kind alliance ... the publication of a white paper entitled Personalized ... The white paper highlights an unprecedented solution for ... engagement to avert strains on the health care ... a range of individually-tailored, pharmacist-provided clinical and consultative ...
(Date:5/20/2013)... -- Volcano Corporation (NASDAQ: VOLC ) a leading ... to enhance the diagnosis and treatment of coronary and ... efforts to expand research and innovation surrounding its physiology ... ® (Instant Wave-Free Ratio™) 1 technologies, via ... 2013 in Paris . ...
(Date:5/20/2013)... Landauer, Inc. (NYSE: LDR ), ... and monitoring, outsourced medical physics services and high quality ... Directors declared, at its meeting on May 16, 2013, ... for the third quarter of fiscal 2013.  The dividend ... of record on June 7, 2013. About ...
Breaking Medicine Technology:RxAlly Releases White Paper on Necessity of Personalized Pharmacist Care 2RxAlly Releases White Paper on Necessity of Personalized Pharmacist Care 3Volcano to Highlight its Physiology Expansion Efforts at EuroPCR 2013 2Volcano to Highlight its Physiology Expansion Efforts at EuroPCR 2013 3Volcano to Highlight its Physiology Expansion Efforts at EuroPCR 2013 4Landauer, Inc. Declares Regular Cash Dividend 2
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: